비침습적 출생전 검사 시장 규모, 점유율, 성장 분석 : 제품별, 검사 방법별, 기술별, 임신 리스크별, 임신 기간별, 용도별, 지역별 - 산업 예측(2025-2032년)
Non-Invasive Prenatal Testing Market Size, Share, Growth Analysis, By Product, By Testing Method, By Technology, By Pregnancy Risk, By Gestation Period, By Application, By Region - Industry Forecast 2025-2032
상품코드:1630593
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 비침습적 출생전 검사(NIPT) 시장 규모는 2023년에 38억 달러로 평가되며, 2024년 41억 6,000만 달러에서 2032년에는 86억 7,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 9.6%로 성장할 전망입니다.
주로 비침습적 산전검사(NIPT)에 초점을 맞춘 비침습적 비경구 스크리닝 시장은 기술 발전과 염색체 이상 위험이 높은 산모 연령 증가에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 이 유전자 검사법은 산모 혈청내 태아 무세포 DNA를 분석하여 다운증후군, 터너증후군과 같은 질환을 조기에 발견할 수 있으며, MaterniT21 PLUS, Harmony, Panorama 등 다양한 NIPT가 현재 전 세계에서 널리 사용되고 있습니다. 비침습적 방법으로의 전환에 힘입어 시장은 확대되고 있습니다. 하지만, 자격이 있는 의료진 부족과 까다로운 규제 요건 등의 문제가 시장 성장에 걸림돌이 될 수 있습니다. 신흥 시장, 특히 아시아태평양은 이 분야의 성장에 새로운 기회를 제공합니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
기술의 진보
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 제품별
시장 개요
소모품
시약
기기
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 검사 방법별
시장 개요
초음파 탐지
생화학 스크리닝 검사
산모 혈장 검사에서의 유리 DNA
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 기술별
시장 개요
NGS
어레이 테크놀러지
PCR
기타
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 임신 리스크별
시장 개요
하이리스크
평균 리스크
저위험
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 임신 기간별
시장 개요
0-12주간
13-24주
25-36주
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 용도별
시장 개요
트리소미
미세결손 증후군
기타
세계의 비침습적 출생전 검사(NIPT) 시장 규모 : 최종사용자별
시장 개요
병원
클리닉
진단 검사실
기타
세계의 비침습적 출생전 검사(NIPT) 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Berry Genomics Co. Ltd.(China)
BGI Genomics Co., Ltd.(China)
Eurofins LifeCodexx GmbH(Germany)
F. Hoffmann-La Roche Ltd.(Switzerland)
GE Healthcare(United States)
Natera, Inc.(United States)
Laboratory Corporation of America Holdings(LabCorp)(United States)
Illumina, Inc.(United States)
Myriad Genetics, Inc.(United States)
Quest Diagnostics Incorporated(United States)
Thermo Fisher Scientific Inc.(United States)
Sonic Healthcare Limited(Australia)
Centogene N.V.(Germany)
PerkinElmer, Inc.(United States)
Cordlife Group Limited(Singapore)
결론과 권장사항
KSA
영문 목차
영문목차
Global Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 3.8 billion in 2023 and is poised to grow from USD 4.16 billion in 2024 to USD 8.67 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).
The non-invasive parenteral screening market, predominantly focused on non-invasive prenatal testing (NIPT), is witnessing significant growth driven by advancements in technology and increasing maternal age, which correlates with higher risks for chromosomal abnormalities. This genetic testing method analyzes fetal cell-free DNA in maternal blood serum, enabling early detection of conditions such as Down syndrome and Turner syndrome. Various NIPTs, including MaterniT21 PLUS, Harmony, and Panorama, are now widely available globally. Facilitated by rising reimbursements for NIPT and a shift towards non-invasive methods, the market is poised for expansion. However, challenges such as a lack of qualified personnel and stringent regulatory requirements may impede progress. Emerging markets, especially in the Asia-Pacific region, present new opportunities for growth in this sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Invasive Prenatal Testing (Nipt) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Non-Invasive Prenatal Testing (NIPT) Market Segmental Analysis
Global Non-Invasive Prenatal Testing (NIPT) Market is segmented by Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User and region. Based on Product, the market is segmented into Consumables, Reagents and Instruments. Based on Testing Method, the market is segmented into Ultrasound Detection, Biochemical Screening Tests and Cell-Free DNA in Maternal Plasma Tests. Based on Technology, the market is segmented into NGS, Array Technology, PCR and Others. Based on Pregnancy Risk, the market is segmented into High Risk, Average Risk and Low Risk. Based on Gestation Period, the market is segmented into 0-12 Weeks, 13-24 Weeks and 25-36 Weeks. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome and Others. Based on End User, the market is segmented into Hospitals, Clinics, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Non-Invasive Prenatal Testing (NIPT) Market
The Global Non-Invasive Prenatal Testing (NIPT) market is driven by the increasing demand for precise and advanced screening techniques that enable early detection of genetic disorders in infants. Companies are focusing on developing innovative noninvasive diagnostic solutions and forming strategic partnerships to enhance their presence in the market. Recent progress in human genome sequencing has significantly improved the identification of aneuploidies in newborns. Notably, Progenity, Inc. launched the Resura Prenatal Diagnostic for Monogenic Disease in 2019, marking a milestone as the first flexible, noninvasive test for single-gene conditions. Furthermore, many countries are adopting non-invasive prenatal screening protocols to effectively detect chromosomal abnormalities.
Restraints in the Global Non-Invasive Prenatal Testing (NIPT) Market
The growth of the Global Non-Invasive Prenatal Testing (NIPT) market faces several significant restraints, primarily stemming from economic and educational barriers. High testing costs, particularly in developing nations where prices range from USD 350 to USD 400, render these tests unaffordable for many, thus hindering widespread adoption. Additionally, a general lack of awareness regarding genetic disorders among the population in emerging markets further complicates acceptance. Coupled with decreasing per capita healthcare expenditure and insufficient reimbursement policies for these tests, these factors collectively contribute to a constrained growth environment for the NIPT market on a global scale.
Market Trends of the Global Non-Invasive Prenatal Testing (NIPT) Market
The Global Non-Invasive Prenatal Testing (NIPT) market is witnessing significant growth as healthcare trends increasingly favor non-invasive methodologies over traditional invasive procedures. Advances in technology and clinical validation have positioned NIPT as the preferred choice for prenatal screening, driven by its therapeutic benefits and cost-effectiveness. Regulatory frameworks in various countries, such as the Netherlands, have further reinforced the adoption of non-invasive diagnostics, establishing them as standard practice. This surge in utilization highlights a shift toward safer prenatal options, with NIPT rapidly gaining traction worldwide, despite the ongoing relevance of invasive tests for specific medical conditions.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Product & CAGR (2025-2032)
Market Overview
Consumables
Reagents
Instruments
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Testing Method & CAGR (2025-2032)
Market Overview
Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Technology & CAGR (2025-2032)
Market Overview
NGS
Array Technology
PCR
Others
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Pregnancy Risk & CAGR (2025-2032)
Market Overview
High Risk
Average Risk
Low Risk
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Gestation Period & CAGR (2025-2032)
Market Overview
0-12 Weeks
13-24 Weeks
25-36 Weeks
Global Non-Invasive Prenatal Testing (NIPT) Market Size by Application & CAGR (2025-2032)
Market Overview
Trisomy
Microdeletion Syndrome
Others
Global Non-Invasive Prenatal Testing (NIPT) Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals
Clinics
Diagnostic Laboratories
Others
Global Non-Invasive Prenatal Testing (NIPT) Market Size & CAGR (2025-2032)
North America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
US
Canada
Europe (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
Brazil
Rest of Latin America
Middle East & Africa (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
GCC Countries
South Africa
Rest of Middle East & Africa
Competitive Intelligence
Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
Company Details
Product Portfolio Analysis
Company's Segmental Share Analysis
Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
Berry Genomics Co. Ltd. (China)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
BGI Genomics Co., Ltd. (China)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Eurofins LifeCodexx GmbH (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
GE Healthcare (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Natera, Inc. (United States)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Laboratory Corporation of America Holdings (LabCorp) (United States)
